SEC Company Response from SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Jan 12, 2021
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: Jan. 12, 2021 · CIK: 0001061027 · Accession: 0001193125-21-007280
AI Filing Summary & Sentiment
File numbers found in text: 333-251567
Letter
SUNESIS PHARMACEUTICALS, INC.
395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
January 12,
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Re: Sunesis Pharmaceuticals, Inc.
Form S-4 Registration Statement (File No. 333-251567)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned registrant hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:30 p.m. Eastern Time on January 14, 2021 or as soon thereafter as is practicable. The undersigned registrant respectfully requests that you notify Marina Remennik of Cooley LLP of such effectiveness by telephone at (650) 843-5124.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Remennik at the telephone number above.
Very truly yours,
SUNESIS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP SUNESIS PHARMACEUTICALS, INC. 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 January 12, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Sunesis Pharmaceuticals, Inc. Form S-4 Registration Statement (File No. 333-251567) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned registrant hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:30 p.m. Eastern Time on January 14, 2021 or as soon thereafter as is practicable. The undersigned registrant respectfully requests that you notify Marina Remennik of Cooley LLP of such effectiveness by telephone at (650) 843-5124. If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Remennik at the telephone number above. Very truly yours, SUNESIS PHARMACEUTICALS, INC. By: /s/ PARVINDER S. HYARE Parvinder S. Hyare Interim Chief Executive Officer